

STATUS OF THE CLAIMS

1-185. (cancelled)

186. (currently amended) A method of topically treating a human having a *Herpes simplex I* virus infection, comprising exposing a surface of a human to a nanoemulsion composition, or a dilution thereof, said nanoemulsion ~~A method for decontaminating a surface of a human of *Herpes simplex I* virus comprising exposing said surface of a human to a composition~~ comprising:

- a) — an oil in water emulsion, comprising;
 - 1) a discontinuous oil phase;
 - 2) an aqueous phase;
 - 3) 3-15% by volume ethanol ~~an alcohol~~; and
 - 4) 3-15% by volume ~~[[a]]~~ surfactant; andwherein said discontinuous oil phase, said aqueous phase, said alcohol, and said surfactant are combined under conditions such that said oil in water emulsion is itself antimicrobial; and
- [[b))] 5) a halogen-containing compound.

187. (currently amended) The method of Claim 186, wherein said surface of a human comprises a skin surface ~~an external surface of a human~~.

188. (currently amended) The method of Claim 186, wherein said surface of a human comprises a mucosal surface ~~an internal portion of a human~~.

189. (currently amended) The method of Claim 186, wherein said nanoemulsion ~~oil in water emulsion~~ further comprises an interaction enhancer ~~a chelating agent~~.

190. (currently amended) The method of Claim 189, wherein said interaction enhancer ~~chelating agent~~ comprises ethylenediaminetetraacetic acid.

191. (previously presented) The method of Claim 186, wherein said oil phase comprises an oil selected from the group consisting of plant oil, animal oil, flavor oil, mineral oil and motor

oil.

192. (previously presented) The method of Claim 191, wherein said plant oil comprises soybean oil.

193. (previously presented) The method of Claim 186, wherein said surfactant is selected from the group consisting of a polysorbate surfactant, a phexypolyethoxyethanol and sodium dodecyl sulfate.

194. (previously presented) The method of claim 193, wherein said polysorbate surfactant comprises TWEEN 20.

195-196. (cancelled)

197. (previously presented) The method of Claim 186, wherein said halogen containing compound comprises cetylpyridinium chloride.

198. (cancelled).

199. (currently amended) The method of Claim 186[[198]], wherein said ~~composition~~topical treatment is formulated in a form selected from the group consisting of a cream, ointment, salve and spray.

200. (new) A method of topically treating a human having a *Herpes simplex I* virus infection, comprising exposing a surface of a human to a nanoemulsion composition, or a dilution thereof, said nanoemulsion_composition comprising:

- 1) 50-80% by volume oil;
- 2) distilled water;
- 3) 3-15% by volume ethanol;
- 4) 3-15% by volume surfactant; and
- 5) cetylpyridinium chloride.

201. (new) The method of Claim 186, wherein said emulsion further comprises ethylenediaminetetraacetic acid.

202. (new) A method of topically treating a human having a *Herpes simplex I* virus infection, comprising exposing a surface of a human to a nanoemulsion composition, or a dilution thereof, said nanoemulsion_composition comprising:

- 1) 3-15% by volume surfactant;
- 2) 3-15% by volume ethanol;
- 3) 50-80% by volume oil;
- 4) cetylpyridinium chloride;
- 5) distilled water; and
- 6) ethylenediaminetetraacetic acid.

203. (new) The method of Claim 202, wherein said cetylpyridinium chloride is 0.5-2% cetylpyridinium chloride.